Genocure, the Largest Shareholder of OliPass,

Leads the Global Regenerative Medicine Market with Asymchem China

Expected Innovation in the KRW 300 Trillion Regenerative Medicine Market

through Next-Generation ‘Recombinant PDRN’ Technology and Asymchem’s CDMO Capabilities

2024-12-12 (Thu)

Asymchem Headquaters, Tianjin, China

Genocure Co., Ltd., a leading company specializing in regenerative medical biomaterials, announced on November 22 that it has signed a Master Service Agreement (MSA) with Asymchem at the company's headquarters in China.

PDRN (Polydeoxyribonucleotide), first developed in Italy 70 years ago, is recognized for its stability as a key ingredient in pharmaceutical production. However, the material is difficult to obtain in large quantities, as it is traditionally sourced from Oncorhynchus keta (chum salmon) and Oncorhynchus mykiss (rainbow trout). Genocure has revolutionized the market by employing advanced regenerative technology to extract PDRN without relying on raw biological materials.

With this agreement, Genocure aims to secure large-scale production and establish a stable global supply chain. The collaboration will leverage Asymchem's global manufacturing capabilities and its renowned quality management system, ensuring reliable production from extraction to DMF certification.

Additionally, Genocure plans to enhance its position in the regenerative medical market through a strategic partnership with OliPass, a KOSDAQ-listed company. This collaboration will focus on the distribution of various finished products, reinforcing both companies' leadership in the PDRN-based regenerative medicine sector.

Asymchem, which gained international recognition for its role as the CDMO for the Pfizer COVID-19 vaccine, has solidified its position as a trusted partner in the global biotechnology and pharmaceutical industries. By combining Genocure’s technology with Asymchem’s manufacturing expertise, this joint venture is expected to drive innovation in the global bio market.

Genocure’s CEO, Oh Bo Gyeong, commented, “Through this agreement and our strategic collaboration with OliPass, Genocure is poised to establish a new paradigm in the global regenerative medicine market. This partnership with Asymchem will help demonstrate our technology on an international scale, solidifying our leadership in the regenerative medicine field.”

Source: JOBPOST (http://www.job-post.co.kr)